SLP vs. DOCS, WIX, CNIC, YOU, SRAD, NET, ARBB, GVP, CYN, and INSE
Should you be buying Sylvania Platinum stock or one of its competitors? The main competitors of Sylvania Platinum include Dr. Martens (DOCS), Wickes Group (WIX), CentralNic Group (CNIC), YouGov (YOU), Stelrad Group (SRAD), Netcall (NET), Arbuthnot Banking Group (ARBB), Gabelli Value Plus+ Trust (GVP), CQS Natural Resources Growth and Income (CYN), and Inspired (INSE). These companies are all part of the "computer software" industry.
Sylvania Platinum vs.
Sylvania Platinum (LON:SLP) and Dr. Martens (LON:DOCS) are both small-cap basic materials companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.
In the previous week, Dr. Martens had 5 more articles in the media than Sylvania Platinum. MarketBeat recorded 6 mentions for Dr. Martens and 1 mentions for Sylvania Platinum. Sylvania Platinum's average media sentiment score of 1.11 beat Dr. Martens' score of 0.45 indicating that Sylvania Platinum is being referred to more favorably in the media.
Dr. Martens has higher revenue and earnings than Sylvania Platinum. Dr. Martens is trading at a lower price-to-earnings ratio than Sylvania Platinum, indicating that it is currently the more affordable of the two stocks.
Sylvania Platinum has a net margin of 8.55% compared to Dr. Martens' net margin of 7.89%. Dr. Martens' return on equity of 18.91% beat Sylvania Platinum's return on equity.
Sylvania Platinum pays an annual dividend of GBX 2 per share and has a dividend yield of 4.0%. Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 5.7%. Sylvania Platinum pays out 93.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Martens pays out 42.5% of its earnings in the form of a dividend. Dr. Martens is clearly the better dividend stock, given its higher yield and lower payout ratio.
Sylvania Platinum has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Dr. Martens has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500.
Sylvania Platinum received 223 more outperform votes than Dr. Martens when rated by MarketBeat users. However, 91.67% of users gave Dr. Martens an outperform vote while only 79.59% of users gave Sylvania Platinum an outperform vote.
17.8% of Sylvania Platinum shares are owned by institutional investors. Comparatively, 69.5% of Dr. Martens shares are owned by institutional investors. 12.2% of Sylvania Platinum shares are owned by company insiders. Comparatively, 4.4% of Dr. Martens shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Dr. Martens beats Sylvania Platinum on 10 of the 17 factors compared between the two stocks.
Get Sylvania Platinum News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sylvania Platinum Competitors List
Related Companies and Tools
This page (LON:SLP) was last updated on 4/20/2025 by MarketBeat.com Staff
